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S184 Oral PresentationsChimerism studies were done using STR at 1, 3, 6, 9 and 12
months post transplant and 3 monthly thereafter. All but one child
engrafted but 4 children had early autologous reconstitution. At 1
year post SCT65%, 9%, 9%and 7%had complete donor chimerism
(CC), highMC (50-95%donor chimerism), lowMC (10-49% donor
chimerism) and very lowMC (\10% donor chimerism) respectively
and these were stable at last follow-up. All childrenwithCC and high
MC are cured of their disease. 26 children (17%) had low or very low
MC. The incidence of low and very lowMCwas significantly higher
with BM (24/109,22%) than with PBSC (2/41,5%).Children with
low and very low levelMChad a poorer prognosis: 5/26 needed a sec-
ond transplant, 3/26 died, 2 had DLI, 1 CD34 top-up, 1 has ongoing
poor immune reconstitution. In conclusion, use of PBSC leads to
good long term chimerism with acceptable GVHD and we advocate
that PBSC should be the stem cell source of choice in RIC SCT in
children.78
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Background: In hematopoietic stem cell transplantation (HSCT)
the occurrence of single nucleotide polymorphisms (SNPs)
within the NOD2/CARD15 gene are associated with higher
susceptibility for graft-versus-host disease (GvHD). Idiopathic
pulmonary syndrome (IPS) is a non-infectious early onset lung
disease (\100days) after HSCT and associated with high mortal-
ity rates. Exact pathogenesis is unknown, but IPS could be con-
sidered as an allo-reactive disease. We retrospectively studied the
clinical impact of NOD2-variants in pediatric HSCT patients
with IPS.
Methods: All patients transplanted between 2004 and 2006 in the
UMCUwere included. For all recipient-donor pairs, mutation anal-
ysis for SNPs 8, 12 and 13 of the NOD2-gene was performed. IPS
was defined as respiratory symptoms with infiltrative changes on
chest X-ray without a direct infectious cause identified (excluding
a respiratory virus). An uni- and multivariable risk factor analyses
was performed using logistic regression and Cox proportional
Hazards.
Results: 57 HSCT patients (29 malignant and 28 for non-malignant
indication) were transplanted with 33 matched and 24 mismatched
donors. Median follow up was 19 months (8-36). The actual proba-
bility of disease free survival was 71%. IPS occurred in 9 patients at
a median of 7 weeks post-HSCT (range 3-12) of whom 4 died. NOD
polymorphisms were found in 6 recipients, 5 donors and in 4 both
donor and recipient. In multivariate regression analysis presence of
a respiratory virus after transplant (p5 0.032, OR 14.41, range
1.27-164.12) and presence of a NOD2-variant (in donor and/or
recipient: p5 0.046, OR 9.15, range 1.04 -80.44) were independent
variables influencing the endpoint IPS.
Conclusion: NOD2 polymorphisms may impact the development
of IPS in addition to the presence of respiratory viral infections. Al-
though more research is warranted on this topic it suggests that
avoiding NOD2 polymorphisms in donors as well as reducing the
pulmonary epithelial damage by screening for viral infections and/
or preventing viral infections prior to SCTmay be important to pre-
vent IPS.79
UK EXPERIENCE OF TREOSULFAN-BASED CONDITIONING REGIMENS IN
CHILDREN WITH PRIMARY IMMUNODEFICIENCY OR SEVERE IMMUNE
DYSREGULATION
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Treosulfan is a bi-functional alkylating agent which causes less
VOD than busulphan and does not require anticonvulsant pro-
phylaxis and drug monitoring. We report the use of treosulfan in
70 children undergoing HCT for PID at two supraregional
transplant centres in the UK. Children received 42 g/m2 or 36 g/m2
treosulfan in combination with either cyclophosphamide 200 mg/kg
(30) or fludarabine 150 mg/m2 (40). All received Campath 1 H
0.3 mg/kg to1.0 mg/kg total dose except those with matched sibling
donors (n5 8), haploidentical CD3/CD19 depleted grafts (n5 3),
CD34+ selected graft with OKT3 (1) and 4 cords (3 of whom had
ATG).
Diagnoses were as follows: severe combined immunodeficiency
(26), Omenn’s Syndrome (7), Wiskott Aldrich syndrome (7), HLH
(5), leukocyte adhesion deficiency (4), chronic granulomatous dis-
ease (3), severe immune dysregulation (3), other PID (15).
Age at transplant ranged from 5 weeks to 14 years 8 months
(median 9 months). 47 patients were 12 months or younger.
Donors were as follows: MSD (8 -1 cord); MFD (13); haploident-
ical (4); URD (45:HLA matched 7-10/10). 16 of 45 were cords (7-
10/10 HLA matched). Follow up is 2- 59 months (median 16
months).
Overall survival was 81%. 13 children died: 6/40 in the treo-
sulfan/fludarabine group and 7/30 in the treosulfan/cyclophos-
phamide group- HLH disease D-1, graft rejection and CMV,
infection (4), GVHD, GVHD+infection etc. Skin toxicity was
common. VOD occurred in 2 children in combination with
cyclophosphamide and both had enterovirus in the gut. 2 patients
rejected (MHC II deficiency successfully retransplanted, ALPS
patient died of CMV before retransplant). Of patients more
than 6 months post transplant 19/28 (68%) who had treosul-
fan/fludarabine and 14/22 (64%) treosulfan/cyclophosphamide
have 100% donor chimerism. The remainder have stable mixed
chimerism.
Outcome is good with low regimen related toxicity. Treosulfan
plus fludarabine was particularly well tolerated. Immune reconstitu-
tion and chimerism were equivalent to busulphan containing regi-
mens. Long-term follow up is required.80
HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX (HCT-
CI) PREDICTS TRANSPLANT OUTCOMES IN PEDIATRIC PATIENTS
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Despite major advances in the field of hematopoietic cell trans-
plant (HCT) in recent years, significant life-threatening complica-
tions still occur. Quantifying this risk for individual patients,
however, is challenging. The HCT-CI combines important comor-
bidities with varying effect on treatment related morbidity and
mortality and combines them into one score. It has been confirmed
as a useful tool in adults undergoing HCT, but has not yet been
validated in children. We conducted a retrospective cohort study
of 252 consecutive pediatric patients undergoing their first alloge-
neic HCT at 4 large centers between January 2008 and May 2009.
Pre-transplant comorbidities were scored prospectively for each
patient using the HCT-CI. The impact of the HCT-CI score on
non-relapse mortality (NRM) and overall survival (OS) was then
analyzed. Underlying diagnoses included leukemia (n5 110),
immune deficiency (n5 63), storage disorders (n5 24), aplastic ane-
mia (n5 22), Fanconi anemia (n5 18), benign hematologic abnor-
malities (n5 9) and other (n5 6). The median age at transplant
was 6 years (range 0.1-20). Donor sources included matched related
donor (n5 74), mismatched related donor (n5 21), HLA matched
unrelated donor (n5 75), mismatched unrelated donor (n5 34)
HCT-CI
Score n
100 day
NRM
(95% CI)
1 year
NRM
(95% CI)
1 year
OS
(95% CI)
Relative
risk of
NRM#
(95%CI)
Relative
risk of
death#
0 185 5%
(2-8%)
12%
(7-17%)
83%
(76-88%)
1.0 1.0
1-2 33 6%
(0-13%)
16
(4-28%)
62%
(41-77%)
1.4
(0.5-3.6)
1.6
(0.6-4.2)
31 34 15%
(3-27%)
32%
(14-50%)
60%
(39-76%)
2.8*
(1.3-6.0)
5.3**
(1.9-14.6)
*P-value\0.05, ** P-value\0.01; #Multivariate analysis adjusted for
age, conditioning intensity and donor type.
Oral Presentations S185and umbilical cord blood (n5 48). Seventy-six percent received
myeloablative conditioning. Scores were distributed as follows:
HCT-CI5 0 (n5 185), 1-2 (n5 33) and 3+ (n5 34). Median
follow-up was 343 days (range 110-624). The 1 year cumulative
incidence of NRM increased (12%, 16% and 32%, respectively;
p5 0.02) and OS decreased (83%, 62% and 60%, respectively;
p5 0.01) with increasing HCT-CI scores. A multivariate analysis
evaluating the effect of HCT-CI on NRM showed that those with
scores of 1-2 and 3+ had a relative risk of death of 1.6 (95%CI 0.6-
4.2, p5 0.37) and 5.3 (95%CI 1.9-14.6, p\0.01) when compared
to those with a score of zero. Similarly, when evaluating OS, those
with scores of 1-2 and 3+ had a relative risk of death of 2.5
(95%CI 1.2-5.1, p5 0.01) and 4.0 (95%CI 1.7-9.0, p\0.01),
respectively. Other factors that had a significant impact on NRM
and OS include donor type and conditioning intensity. HCT-CI
score appears to predict NRM andOS in pediatric patients undergo-
ing HCT and may be a useful tool to assess risk, guide counseling in
the pre-transplant setting and devise innovative therapies for the
highest risk group.81
CORRECTION OF IMMUNE DEFECT, EXCELLENT SURVIVAL, AND LONG-
TERM DONOR CHIMERISM IN CHILDREN WITH CHRONIC GRANULOMA-
TOUS DISEASE AFTER MYELOABLATIVE TRANSPLANTATION ACROSS DO-
NOR AND GRAFT SOURCES
Tewari, P., Martin, P.L., Parikh, S.H., Szabolcs, P., Page, K.M.,
Driscoll, T.A., Kurtzberg, J., Prasad, V.K. Duke University Medical
Center, Durham, NC
Background: Allogeneic hematopoietic stem cell transplantation
(HSCT) is curative in chronic granulomatous disease (CGD) but ac-
cess to HSCT is limited by donor availability and preparative regi-
men able to induce durable donor chimerism.
Methods: Ten children (one female, 6 Caucasian, 3 CMV sero-
positive) with clinically severe CGD (x-linked, n5 6; autosomal,
n5 4) received myeloablative HSCT at our center between
1997 and 2009. Seven were previously treated with interferon.
Pretransplant morbidities included a median of 3 (range, 2-9) se-
rious bacterial/fungal infections, including one invasive pulmonary
aspergilosis treated with antifungals for .1 year, and one primary
graft failure (GF) after reduced intensity HSCT at another insti-
tution. At transplant, median age and weight were 10.25 years
(range, 0.7-11.7) and 19.6 kg (range, 9.6-60). Graft sources were
matched sibling bone marrow (SibBM) in 5, unrelated cord blood
(UCB) in 4 and sibling cord blood (SibCB) in 1 patient. SibBM
and SibCB donors were 6/6 HLA matched. UCB units were 4/
6 (n5 1) or 5/6 (n5 3) and contained a median of 3.810^7 pre-
cyropreservation nucleated cells/kg. SibBM patients received
Busulfan (Bu) and Cyclophosphamide (Cy)6ATG. Primary GF
following Bu/Cy/ATG in the first UCB recipient led to the use
of Fludarabine(Flu)/Bu/Cy/ATG in subsequent CB patients.
Five patients received irradiated granulocyte transfusions (4 from
GCSF mobilized family donors; one from Red Cross) until
engraftment.Results: Currently, all patients are alive, free of infections, doing
well (Lansky, 70-100) and have normal respiratory bursts at a me-
dian follow-up of 56 (range, 3-144) months. Two UCB recipients
developed primary GF but were successfully retransplanted with
a second UCB unit after additional conditioning with Flu/Cy
with TBI (200 cGy) or Campath. One patient developed interstitial
pneumonitis post transplant. Chimerism was all donor in 8 and
94% and 74% in the other two patients. Grade III/IV acute
GvHD developed in two and extensive chronic GvHD in 1 patient.
Conclusions: Myeloablative allogeneic HSCT with a HLA-
matched sibling or UCB donor corrects neutrophil dysfunction, re-
sults in durable high-level chimerism, and excellent survival with
minimal GvHD. Durable engraftment was acheived after second
transplant in patients who had GF after the first transplants. Patients
transplanted with UCB had equivalent outcomes to those with
HLA-matched siblings.
# of Patients %Alive and Disease Free 10 100
Most Recent Chimerism
.98% 8 80
.75% 10 100
Neutrophil Engraftment Median Range
SibCB & UCB 29 days 16-43
SibBM 16 days 11-20
Platelet Engraftment
SibCB & UCB 72 days 28-172
SibBM 40 days 33-5982
RISING NUMBERS OF RECENT THYMIC EMIGRANTS (RTE) WITHIN THE
FIRST YEAR AFTER UNRELATED CORDBLOOD TRANSPLANT (UCBT) PRE-
DICT OVERALL SURVIVAL FOR CHILDREN: A MULTIVARIATE ANALYSIS
FOLLOWING MYELOABLATIVE CONDITIONING AND A SINGLE UNIT
GRAFT
Wilfret, D.A.1, Mendizabal, A.2, Reese, M.1, Page, K.M.1, Prasad, V.K.1,
Kurtzberg, J.1, Szabolcs, P.1 1Duke University, Durham, NC; 2The
EMMES Corporation, Rockville, MD
Opportunistic infections and leukemic relapse negatively impact
overall survival after UCBT. Recovery of antiviral T cell function
correlated with reduced risk of relapse in the COBLT study, pre-
sumably due to enhanced GVL effect.
Objectives: We set out to determine if the tempo and quality of
immune recovery during the first year after UCBT can predict
survival.
Methods: A pediatric cohort (n5 93) was transplanted between
July 2005 and September 2008 at a single center. All studied pa-
tients engrafted fully following myeloablative conditioning and
a single CB graft. Immune reconstitution was monitored longitudi-
nally by a uniform 4 color FACS panel to enumerate B and NK
cells along with DC and T cell subsets. Two sided t-test was em-
ployed in univariate analyses to test for differences between the
mean values generated from all time points (n5 432) between
those alive and those who eventually died. Logistic regression
models were created comparing patients above and below the me-
dian values obtained during the first 365 days post-UCBT using
forward selection method.
Results: 63 of 93 children were transplanted for non-malignant
diseases and 19 of them were minority. The median age was 2.1
years (range 0.1 to 18), 58%were male, 36% were 4/6, 41% were
5/6, and 23% were 6/6 HLA match. Overall, 67 patients (72%)
are alive. Univariate analysis demonstrated that those who never
died had significantly more circulating CD4+, CD8 +T cells, B
cells, Tregs, RTE, and plasmacytoid DC. In this cohort where
all studied patients have already engrafted and where death was in-
frequent, gender, race, CMV serology, TNC, CD34+ cell dose,
TBI, acute GVHD 2-4 or 3-4 had no impact on overall survival.
